With a revenue increase of 30.21% in the third quarter 2026, year on year to cumulative value of $470 million, Krystal Biotech Inc 's revenue per employee grew on a trailing twelve months basis to $ 1,593,305. The productivity of Krystal Biotech Inc 's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 58 other companies have achieved higher revenue per employee. While Krystal Biotech Inc 's total ranking has deteriorated compared to the previous quarter from 431 to 635. Krystal Biotech Inc has 295 employees.
In a groundbreaking announcement, Krystal Biotech, a clinical-stage biotechnology company, has unveiled remarkable early evidence of monotherapy activity in heavily pre-treated patients with advanced non-small cell lung cancer (NSCLC). This exciting development comes at a critical time, as the medical community seeks innovative treatments for patients battling this aggressive form of cancer, particularly after traditional therapies have failed. The Significance of the Findings The initial clinical data released from the ongoing trial paints an optimistic picture for those who have exhausted the standard anti-PD-1 therapies. The results indicate a 27% overall response rate (ORR) and an impressive 73% disease control rate (DCR) among participants. These statistics suggest not only the potential for tumor shrinkage but also the possibility of stabilizing disease progression in a patient population that has limited options left.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
